MX2023002650A - Metodos de tratamiento del dolor por cancer mediante la administracion de un inhibidor de pd-1. - Google Patents
Metodos de tratamiento del dolor por cancer mediante la administracion de un inhibidor de pd-1.Info
- Publication number
- MX2023002650A MX2023002650A MX2023002650A MX2023002650A MX2023002650A MX 2023002650 A MX2023002650 A MX 2023002650A MX 2023002650 A MX2023002650 A MX 2023002650A MX 2023002650 A MX2023002650 A MX 2023002650A MX 2023002650 A MX2023002650 A MX 2023002650A
- Authority
- MX
- Mexico
- Prior art keywords
- patient
- inhibitor
- administering
- methods
- cancer
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000012270 PD-1 inhibitor Substances 0.000 title abstract 3
- 239000012668 PD-1-inhibitor Substances 0.000 title abstract 3
- 229940121655 pd-1 inhibitor Drugs 0.000 title abstract 3
- 206010058019 Cancer Pain Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 230000000202 analgesic effect Effects 0.000 abstract 3
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente descripción provee métodos para tratar o inhibir el dolor por cáncer en un paciente que lo necesite, incluida la selección de un paciente con cáncer y la administración al paciente de una cantidad terapéuticamente eficaz de un inhibidor de muerte programada 1 (PD-1). La presente descripción también provee métodos para reducir el uso de analgésicos en un paciente que lo necesite, incluida la selección de un paciente con cáncer y la administración al paciente de una cantidad terapéuticamente eficaz de un inhibidor de PD-1, en donde el paciente está siendo tratado con una terapia con analgésicos de base antes de la administración del inhibidor de PD-1. En algunas modalidades, los métodos descritos conducen al mismo tiempo a la regresión del tumor, la reducción del dolor y la reducción del uso de la terapia con analgésicos.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063074282P | 2020-09-03 | 2020-09-03 | |
| US202163161519P | 2021-03-16 | 2021-03-16 | |
| US202163186375P | 2021-05-10 | 2021-05-10 | |
| EP21315132 | 2021-07-29 | ||
| PCT/US2021/048785 WO2022051448A1 (en) | 2020-09-03 | 2021-09-02 | Methods of treating cancer pain by administering a pd-1 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002650A true MX2023002650A (es) | 2023-06-08 |
Family
ID=77924529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002650A MX2023002650A (es) | 2020-09-03 | 2021-09-02 | Metodos de tratamiento del dolor por cancer mediante la administracion de un inhibidor de pd-1. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11932692B2 (es) |
| EP (1) | EP4208258A1 (es) |
| JP (1) | JP2023542490A (es) |
| KR (1) | KR20230061499A (es) |
| CN (1) | CN116194142A (es) |
| AU (1) | AU2021337650A1 (es) |
| CA (1) | CA3170207A1 (es) |
| IL (1) | IL300975A (es) |
| MX (1) | MX2023002650A (es) |
| WO (1) | WO2022051448A1 (es) |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4896327B2 (ja) | 1999-08-23 | 2012-03-14 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｐｄ−１、ｂ７−４の受容体、およびその使用 |
| ES2654064T3 (es) | 2002-07-03 | 2024-03-13 | Ono Pharmaceutical Co | Composiciones inmunopotenciadoras que comprenden anticuerpos anti-PD-L1 |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| CN101213297B (zh) | 2005-05-09 | 2013-02-13 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及单独使用或与其它免疫治疗剂联合使用抗pd-1抗体来治疗癌症的方法 |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| CA2698419C (en) | 2007-09-07 | 2019-11-12 | Edward Dolk | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
| MX349463B (es) | 2008-09-26 | 2017-07-31 | Univ Emory | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
| PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| RU2604814C2 (ru) | 2011-07-24 | 2016-12-10 | Кьюртек Лтд. | Варианты гуманизированных иммуномодулирующих моноклональных антител |
| RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
| LT2883449T (lt) | 2012-03-16 | 2018-05-10 | Regeneron Pharmaceuticals, Inc. | Histidinu modifikuoti lengvosios grandinės antikūnai ir juos gaminantys genetiškai modifikuoti graužikai |
| SG11201407859YA (en) | 2012-05-31 | 2014-12-30 | Genentech Inc | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| EP3553086A1 (en) | 2012-05-31 | 2019-10-16 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind pd-l1 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| CA2956399A1 (en) | 2014-08-05 | 2016-02-11 | Cb Therapeutics, Inc. | Anti-pd-l1 antibodies |
| US10336824B2 (en) | 2015-03-13 | 2019-07-02 | Cytomx Therapeutics, Inc. | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof |
| KR20180040138A (ko) | 2015-07-13 | 2018-04-19 | 싸이톰스 테라퓨틱스, 인크. | 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법 |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| MX2018012132A (es) | 2016-04-07 | 2019-03-28 | Chemocentryx Inc | Reduccion de carga tumoral mediante administracion de antagonistas de ccr1 en combinacion con inhibidores de muerte-1 programada (pd-1) o inhibidores de ligando-1 de muerte-1 programada (pd-l1). |
| TWI755395B (zh) * | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| US11007250B2 (en) | 2017-05-12 | 2021-05-18 | Duke University | Methods and kits for treating pain |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| CN113507963A (zh) | 2019-01-21 | 2021-10-15 | 赛诺菲 | 用于晚期实体瘤癌症的治疗性rna及抗pd1抗体 |
-
2021
- 2021-09-02 WO PCT/US2021/048785 patent/WO2022051448A1/en active Application Filing
- 2021-09-02 AU AU2021337650A patent/AU2021337650A1/en active Pending
- 2021-09-02 IL IL300975A patent/IL300975A/en unknown
- 2021-09-02 JP JP2023514719A patent/JP2023542490A/ja active Pending
- 2021-09-02 EP EP21778317.4A patent/EP4208258A1/en active Pending
- 2021-09-02 MX MX2023002650A patent/MX2023002650A/es unknown
- 2021-09-02 US US17/464,819 patent/US11932692B2/en active Active
- 2021-09-02 KR KR1020237011352A patent/KR20230061499A/ko unknown
- 2021-09-02 CN CN202180054362.7A patent/CN116194142A/zh active Pending
- 2021-09-02 CA CA3170207A patent/CA3170207A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3170207A1 (en) | 2022-03-10 |
| JP2023542490A (ja) | 2023-10-10 |
| US20220064304A1 (en) | 2022-03-03 |
| KR20230061499A (ko) | 2023-05-08 |
| AU2021337650A1 (en) | 2023-05-04 |
| IL300975A (en) | 2023-04-01 |
| AU2021337650A9 (en) | 2024-06-13 |
| EP4208258A1 (en) | 2023-07-12 |
| WO2022051448A1 (en) | 2022-03-10 |
| CN116194142A (zh) | 2023-05-30 |
| US11932692B2 (en) | 2024-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4327882A3 (en) | Enpp1 inhibitors and their use for the treatment of cancer | |
| MX2023002248A (es) | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. | |
| MX2021009269A (es) | Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria. | |
| MX2021005651A (es) | Combinacion farmaceutica para el tratamiento contra el cancer. | |
| ZA202109010B (en) | Compounds and methods for the treatment of covid-19 | |
| MX2022012992A (es) | Inhibidores de kif18a para el tratamiento de enfermedades neoplasicas. | |
| WO2009129509A3 (en) | Methods and compositions for treating post-operative pain comprising a local anesthetic | |
| HK1078771A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer | |
| MX2023014028A (es) | Inhibidores de cinasa de punto de control 1 (chk1) y usos de los mismos. | |
| MX2022009091A (es) | Anticuerpos para usarse en terapia. | |
| MX2023010657A (es) | Inhibidores de los retrotransposones largos intercalados del elemento 1 (line-1) para tratar enfermedades del sistema nervioso central (snc) y sistemicas. | |
| BR112022010806A2 (pt) | Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama | |
| BRPI0508982A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11 | |
| MX2022014356A (es) | Ciertas composiciones quimicas y metodos de uso de las mismas. | |
| MX2023003332A (es) | Inhibidores del elemento 1 interdispersado largo (line-1) para el tratamiento de enfermedades. | |
| MX2023002650A (es) | Metodos de tratamiento del dolor por cancer mediante la administracion de un inhibidor de pd-1. | |
| TW200724158A (en) | Combination therapy in the treatment of cancer | |
| MX2022001450A (es) | Metodo de tratamiento del cancer. | |
| EA202290027A1 (ru) | Способы и композиции для улучшения результатов лечения пациентов с раком | |
| MX2020007817A (es) | Prevención y tratamiento del trastorno del sueño. | |
| WO2023019095A3 (en) | Momelotinib combination therapy | |
| MX2023009279A (es) | Metodos de tratamiento de cancer mediante la administracion de un inhibidor de pd-1 como neoadyuvante. | |
| WO2022271810A3 (en) | Bicyclic peptidyl pan-ras inhibitors | |
| BR112023023702A2 (pt) | Métodos de tratamento da cistite intersticial/síndrome da dor na bexiga | |
| MX2022011725A (es) | Metodos para tratar una lesion pulmonar con inhibidores de cgrp. |